Trusted by Industry Leaders

SAMSON MEDICAL TECHNOLOGIES

samsonmedtech.com

Australian Biotechnologies

Life Enhancing Allografts

ausbiotech.com.au

CHANGING THE WAY YOU DO RHINOPLASTY

Costal Cartilage rib grafts are regularly used in rhinoplasty. Since the use of autogenous rib cartilage carries a risk of both donor site and rhinoplasty complications, alternative sources of cartilage grafts are becoming the preferred option for suitable rhinoplasty cases. Costal cartilage allografts (also known as Irradiated Homograft Cartilage Grafts – IHCG) are considered a convenient alternative or even a primary grafting material when the patient does not have adequate quantities of septal or auricular cartilage remaining to provide the correction, or when the shape or quality of the cartilage does not adequately provide the structure required.

Australian owned Samson Medical Technologies is the Australian and New Zealand Plastic, Reconstructive and Oral Maxillofacial clinical support services partner of Australian Biotechnologies, the leading allograft manufacturer of human donated tissue. Through this partnership, Samson has initiated many innovative new product developments, including the game changing costal cartilage allograft, to the Australian market since November 2019, following an extensive two-year TGA registration process.

Andrew Nutman, CEO of Samson Medical Technologies said: "After two and a half years of the costal cartilage allograft being in surgeon's hands in the market, we have received an overwhelmingly positive response from the industry and key leaders in their field.

"Given the remarkable patient outcomes and long-term results with over 1,000 cases completed, we can confidently say the product has been a great success and is now seen as the 'go to' product when requiring rib cartilage."

AUSTRALIAN MANUFACTURED AND DISTRIBUTED

An Australian operation, from manufacturing and distribution to clinical support ensures the most premium quality product available on the market, ultimately producing the best patient outcomes and success rates.

The manufacturing and distribution of the costal cartilage allograft, provided by Australian Biotechnologies, adheres to the stringent TGA (Therapeutic Goods Association) requirements for donor acceptance and testing, as well as the processing and sterilisation protocols.

FEEDBACK FROM LEADING SURGEONS OUTLINING KEY ALLOGRAFT PRODUCT BENEFITS

Over 100 surgeons Australia-wide are embracing this innovation and have been actively using the costal cartilage allograft for many of their rhinoplasty related surgeries since launch. Samson Medical Technologies has received extremely positive feedback from many leading surgeons highlighting the allograft product benefits, including:

Potential for lower costs due to less theatre time

It is readily available and significantly shortens operating time by eliminating graft harvest therefore avoiding donor site morbidity and has excellent tissue tolerance[1]. The costal cartilage allograft product is also fully rebatable through Private Health Insurance.

Perichondrium is still attached to the cartilage

Unlike an autograft, the costal cartilage allograft product is supplied with perichondrium still attached to the cartilage. This allows it to be used as an on lay under the skin. This valuable benefit is unable to be achieved with an autograft due to the risk of pneumothorax.

Risks are significantly lower than harvest an autograft, reducing risk in harvest site morbidity

Removing the need to harvest an autograft equates to a much lower risk of surgical complications, including:

- **No risk of pneumothorax or haemothorax.**
- **Only one surgical site**, meaning the patient recovery downtime is significantly decreased, there is less post-surgery discomfort and there is no scar on the chest. For some patients, the major postoperative complaint is the donor rib surgical site. Speeding up surgery and recovery time allows patients to return to regular activities sooner.
- **Surgical time is reduced**, equating to less time that the patient is under general anaesthetic, lowering the risks associated.
- **No risk of harvesting a calcified autograft**, resulting in better patient outcomes.

The results of clinical studies[2] indicate safety and reliability and justify the use of costal cartilage allografts for primary and revision rhinoplasty without creating donor site morbidity, providing considerable benefits for the patient. The studies have also shown that the rate of complication is no greater than complication when autologous grafts are used[3].

About Samson Medical Technologies

At the forefront of medical innovation

Samson Medical Technologies is one of Australia's fastest growing biological and medical device distribution companies, at the forefront of new product developments, global trends and treatments in demand.

100% Australian owned, Samson Medical Technologies takes pride in offering one of the finest clinical support programs in the industry and represents technologies and brands that make clinical sense to practitioners and provide better patient outcomes.

About Australian Biotechnologies

Australian Biotechnologies Pty Ltd. is a specialist in allograft tissue processing and deliver optimal solutions for all clinical biologic and allograft requirements, to supply allografts for a wide range of patient needs and surgical procedures both nationally and internationally.

Australian Biotechnologies' world-class manufacturing facilities and proprietary processing technology have become renowned as the leader of allograft production. Through development of pioneering processes, cultivation of the highest level of quality standards, and a measure of success based on patient outcomes, the company has grown steadily year-on-year since its foundation.

During a 22-year history, Australian Biotechnologies has successfully introduced and launched new allograft and biologic products, and to date has supplied over 150,000 allografts to the Australian community.

References:

1. Strauch B, Wallach SG (2002) Reconstruction with Irradiated Homograft Costal Cartilage. Plast. Reconstr. Surg. 111: 2405, 2003
2. Kridel RW, Ashoori F, Liu ES, Hart CG (2009) Long-term use and follow-up of irradiated homologous costal cartilage grafts in the nose. Arch Facial Plast Surg 11(6):378–394
3. Herman CK, Strauch B (2008) Dorsal Ausgmentation Rhinoplasty with Irradiated Homograft Costal Cartilage